- In November 2023, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the approval of a generic version of Forteo (teriparatide) in the United States, expanding accessible options for osteoporosis treatment via auto injector
- In May 2023, Coherus BioSciences, a leading global biosimilar company, announced the commercial launch of UDENYCA (pegfilgrastim-cbqv) in a single-dose prefilled auto-injector package in the U.S. market. This biosimilar is administered the day following chemotherapy to reduce the risk of infection. Similarly, Boehringer Ingelheim also commercially launched a new autoinjector option for its interchangeable biosimilar to Humira, Cyltezo Pen, in the U.S. marketplace
- In April 2023, Ypsomed Holding AG (Switzerland) opened a production facility in the Changzhou National Hi-tech District in China to cater to the rapidly growing Chinese market for injection systems, demonstrating strategic expansion to meet global demand for auto injectors
- In January 2023, Novo Nordisk signed a long-term supply agreement with Ypsomed for the delivery of auto injectors for its GLP-1 drugs, highlighting the increasing demand for auto injectors for chronic conditions such as diabetes and obesity
